Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy
Abstract The two main objectives of this analysis were to (i) characterize the relationship between immunoglobulin (Ig) exposure and chronic inflammatory demyelinating polyneuropathy (CIDP) disease severity using data from 171 patients with CIDP who received either subcutaneous Ig (IgPro20; Hizentra...
Enregistré dans:
Auteurs principaux: | Michael A. Tortorici, Theresa Yuraszeck, David Cornblath, Vera Bril, Hans‐Peter Hartung, Gen Sobue, Richard A. Lewis, Ingemar S. J. Merkies, John‐Philip Lawo, Michaela Praus, Billie L. Durn, Orell Mielke, Xuewen Ma, Petra Jauslin, Marc Pfister, Ivo N. vanSchaik, the PATH study group |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/864b1de80a0d49abab9c2cf35b4c5ae2 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study.
par: Samantha K Dunnigan, et autres
Publié: (2014) -
Evolving Immunologic Perspectives in Chronic Inflammatory Demyelinating Polyneuropathy
par: Rajabally YA, et autres
Publié: (2020) -
Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins
par: Mohamed Mahdi-Rogers, et autres
Publié: (2010) -
Metaheuristics for pharmacometrics
par: Seongho Kim, et autres
Publié: (2021) -
Corneal inflammatory cell infiltration predicts disease activity in chronic inflammatory demyelinating polyneuropathy
par: Jeremias Motte, et autres
Publié: (2021)